公开(公告)号：US11464838B2

公开(公告)日：2022-10-11

申请号：US15562710

申请日：2016-04-01

Applicant: COLORADO STATE UNIVERSITY RESEARCH FOUNDATION

Inventor： Lyndah Chow ,  Steven W. Dow ,  Amanda M. Guth ,  Daniel P. Regan

IPC: A61K39/00 ,  C12N5/095 ,  A61K31/4178 ,  A61K31/453

Abstract: The present invention provides cancer stem cell vaccines useful for treating or preventing a variety of tumors, as well as related methods of producing cancer stem cells and antigens thereof and producing vaccine adjuvants with enhanced activity for use with the stem cell vaccines.

公开(公告)号：US11464785B2

公开(公告)日：2022-10-11

申请号：US16191119

申请日：2018-11-14

Applicant: Omeros Corporation

Inventor： Gregory A. Demopulos ,  George A. Gaitanaris ,  Roberto Ciccocioppo

IPC: A61K31/4162 ,  A61K31/4439 ,  A61K31/505 ,  A61K31/44 ,  A61K31/4015 ,  A61K31/381 ,  A61K31/551 ,  A61K31/5513 ,  A61K31/135 ,  A61K31/4025 ,  A61K31/4178 ,  A61K31/519 ,  A61K31/4985 ,  A61K31/35 ,  A61K31/433 ,  A61K31/435 ,  A61K31/46 ,  A61K31/527 ,  A61K31/496 ,  A61K31/53 ,  A61K31/5377 ,  A61K31/465 ,  A61K31/55 ,  A61K31/517 ,  A61K31/485 ,  A61K31/454 ,  A61K31/385 ,  A61K31/357 ,  A61K31/337 ,  A61K31/197 ,  A61K31/137 ,  A61K45/06

Abstract: This disclosure is directed to treatment of addictions and primary impulse-control disorders using phosphodiesterase 7 (PDE7) inhibitors, alone or in combination with other therapeutic agents.

公开(公告)号：US20220305019A1

公开(公告)日：2022-09-29

申请号：US17701349

申请日：2022-03-22

Applicant: Ingenious Ingredients, LP

Inventor： Martin Purpura ,  Ralf Jäger ,  Shawn Wells ,  Kylin Liao

IPC: A61K31/522 ,  A61K36/82 ,  A61K31/205 ,  A61K31/165 ,  A61K31/475 ,  A61K36/38 ,  A61K36/258 ,  A61K31/145 ,  A61K31/352 ,  A61K31/045 ,  A61K38/17 ,  A61K31/593 ,  A61K31/122 ,  A61K33/06 ,  A61K36/81 ,  A61K31/4178 ,  A61K31/198 ,  A61K31/197 ,  A61K31/12 ,  A61K31/685 ,  A61K33/04 ,  A61P3/04

Abstract: Disclosed herein are methods for promoting weight loss in a subject by administering to the subject a composition comprising from about 2 mg to about 800 mg of paraxanthine. In certain aspects, paraxanthine is present in the composition in amount from about 20 mg to about 600 mg. In further aspects, paraxanthine is present in the composition in amount from about 50 mg to about 400 mg. According to certain embodiments, weight loss is promoted through inducing thermogenesis in the subject. In further embodiments, weight loss is promoted through enhancing lipolysis in the subject. According to certain implementations, administration of the composition to the subject decreases the respiratory quotient in the subject by at least about 10%.

公开(公告)号：US20220280489A1

公开(公告)日：2022-09-08

申请号：US17633128

申请日：2020-08-05

Applicant: TAIHO PHARMACEUTICAL CO., LTD.

Inventor： Hiromi MURAOKA ,  Naoki ARIMURA

IPC: A61K31/437 ,  A61K31/502 ,  A61K31/55 ,  A61K31/5025 ,  A61K31/454 ,  A61K31/4178 ,  A61P35/00

Abstract: Provided is a novel method for treating cancer with a high antitumor effect. The present invention provides an antitumor agent comprising an azabicyclo compound of the following Formula (I) or a salt thereof and a poly(adenosine 5′-diphosphate-ribose) polymerase inhibitor which are administered in combination.

公开(公告)号：US11426394B2

公开(公告)日：2022-08-30

申请号：US17340486

申请日：2021-06-07

Applicant: Assa Weinberg

Inventor： Assa Weinberg

IPC: A61K31/4422 ,  A61P27/02 ,  A61K31/04 ,  A61K31/138 ,  A61K31/165 ,  A61K31/166 ,  A61K31/167 ,  A61K31/18 ,  A61K31/216 ,  A61K31/277 ,  A61K31/345 ,  A61K31/401 ,  A61K31/403 ,  A61K31/404 ,  A61K31/41 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/4245 ,  A61K31/4439 ,  A61K31/472 ,  A61K31/50 ,  A61K31/517 ,  A61K31/549 ,  A61K31/55 ,  A61K31/554 ,  A61K31/675

Abstract: A method is provided to prevent and to treat Macular Degeneration by using Calcium Channel Blockers, Angiotensin-Converting Enzyme (ACE) Inhibitors, or Angiotensin Receptor Blockers (ARB), and more particularly, to a method to prevent and treat Macular Degeneration by using Calcium Channel Blockers, Angiotensin-Converting Enzyme Inhibitors, or Angiotensin Receptor Blockers that are not taken orally, but administered by ophthalmic preparation directly onto or into the eye where Macular Degeneration is formed, to increase the capillary network and blood supply to the retinal macula.

公开(公告)号：US11419878B2

公开(公告)日：2022-08-23

申请号：US16089274

申请日：2017-03-27

Applicant: Intercept Pharmaceuticals, Inc.

Inventor： Tadashi Namisaki ,  Hitoshi Yoshiji

IPC: A61K31/575 ,  A61P1/16 ,  A61K31/41 ,  A61K31/4178 ,  A61K31/42 ,  A61K31/454 ,  A61K45/06 ,  A61K31/4184 ,  A61K31/4245

Abstract: The present invention provides an NASH therapeutic agent including: an FXR agonist, preferably obeticholic acid or a pharmaceutically acceptable salt thereof; and an ARB or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20220257556A1

公开(公告)日：2022-08-18

申请号：US17630692

申请日：2020-07-29

Applicant: BioCryst Pharmaceuticals, Inc.

Inventor： Yarlagadda S. Babu ,  William P. Sheridan

IPC: A61K31/343 ,  A61K9/00 ,  A61K31/443 ,  A61K31/4436 ,  A61K31/4725 ,  A61K31/5377 ,  A61K31/4178 ,  A61K31/423 ,  A61K31/53 ,  A61K31/416 ,  A61K31/381 ,  A61K31/4525 ,  A61K31/4355 ,  A61K31/519 ,  A61K31/4025 ,  A61P7/06 ,  A61P37/06

Abstract: Disclosed are compounds and pharmaceutically acceptable salts and prodrugs thereof, which are inhibitors of the complement system. Also provided are oral dosage forms comprising such a compound, salt, or prodrug. Also disclosed are methods of using the compounds, salts, and prodrugs, and oral dosage forms thereof, in the treatment or prevention of a disease or condition characterized by aberrant complement system activity (e.g., paroxysmal nocturnal hemoglobinuria).

公开(公告)号：US11413306B2

公开(公告)日：2022-08-16

申请号：US15766272

申请日：2016-10-06

Applicant: AlgiPharma AS

Inventor： Arne Dessen ,  Philip Rye

IPC: A61K31/734 ,  A61P31/10 ,  A61K9/00 ,  A61K45/06 ,  A61K31/165 ,  A61K31/404 ,  A61K31/415 ,  A61K31/4375 ,  A61K31/47 ,  A61K31/7036 ,  A61K31/4178 ,  A61K31/365 ,  A61K31/4245 ,  A61K31/352 ,  A61K31/192 ,  A61K36/03 ,  A61K31/522 ,  A61K31/4422 ,  A61P31/04

Abstract: The invention provides a method for the treatment or prevention of microbial overgrowth in at least part of the intestinal tract of a subject, said method comprising administering an effective amount of an alginate oligomer to a subject in need thereof. Also provided is an alginate oligomer for use in the treatment or prevention of microbial overgrowth in at least part of the intestinal tract of a subject and a product containing an alginate oligomer and further pharmaceutical for the treatment of intestinal microbial overgrowth and/or a CFTR modulator as a combined preparation for separate, simultaneous or sequential use in the treatment or prevention of microbial overgrowth in at least part of the intestinal tract of a subject.

公开(公告)号：US20220235018A1

公开(公告)日：2022-07-28

申请号：US17712001

申请日：2022-04-01

Applicant: Valo Health, Inc.

Inventor： Jennifer Lee ,  Nicholas Barczak ,  Jaime A. Escobedo ,  Chiara Conti ,  Bingsong Han ,  David R. Lancia, JR. ,  Cuixian Liu ,  Matthew W. Martin ,  Pui Yee Ng ,  Aleksandra Rudnitskaya ,  Jennifer R. Thomason ,  Xiaozhang Zheng

IPC: C07D263/58 ,  A61P35/00 ,  A61K31/403 ,  A61K31/404 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/4188 ,  A61K31/4192 ,  A61K31/422 ,  A61K31/423 ,  A61K31/4245 ,  A61K31/427 ,  A61K31/428 ,  A61K31/435 ,  A61K31/437 ,  A61K31/438 ,  A61K31/4439 ,  A61K31/4709 ,  A61K31/4985 ,  A61K31/506 ,  A61K31/52 ,  A61K31/5377 ,  A61K31/5383 ,  A61K45/06 ,  C07C53/06 ,  C07D209/40 ,  C07D209/54 ,  C07D221/20 ,  C07D235/30 ,  C07D277/82 ,  C07D401/04 ,  C07D401/06 ,  C07D401/14 ,  C07D403/04 ,  C07D403/06 ,  C07D405/04 ,  C07D413/06 ,  C07D413/12 ,  C07D413/14 ,  C07D417/06 ,  C07D473/00 ,  C07D487/04 ,  C07D491/056 ,  C07D491/107 ,  C07D498/04

Abstract: The present invention provides methods and uses of inhibitors of histone deacetylase 11 (HDAC11) in the treatment of diseases and/or disorders, such as, for example, cell proliferative diseases.

公开(公告)号：US20220226287A1

公开(公告)日：2022-07-21

申请号：US17708466

申请日：2022-03-30

Applicant: Ocuphire Pharma, Inc.

Inventor： William H. Pitlick ,  Alan R. Meyer ,  Mina Sooch ,  Konstantinos Charizanis ,  Bernhard Hoffmann

IPC: A61K31/417 ,  A61P27/08 ,  A61P27/10 ,  A61K31/4178

Abstract: The invention provides methods, compositions, and kits containing an alpha-adrenergic antagonist, such as phentolamine, for use in monotherapy or as part of a combination therapy to treat patients suffering from presbyopia, mydriasis, and/or other ocular disorders.